ABSTRACT
No products of the biotechnology revolution will likely have a greater legacy than recombinant vaccines. Clinical efficacy trials of new acellular pertussis vaccines have recently been completed; among them, a vaccine containing a genetically modified pertussis toxin showed superior effectiveness in protection against disease caused by Bordetella pertussis. The foundations for this vaccine derive from the work of many investigators, but most notably: Japanese researchers who demonstrated the potential for subcomponents of B. pertussis, and particularly pertussis toxin, to confer protective immunity; research teams in Italy and the United States who cloned and sequenced the pertussis toxin operon; and our own group who molecularly dissected the toxin molecule to produce recombinant analogs of this heterohexameric protein that retained protective immunogenicity yet lacked the intrinsic enzyme activity that results in the adverse reactogenic effects of immunization. Another result of the research leading to this new pertussis vaccine is an intimate understanding of the relationship between form and function in the ADP-ribosylating toxins with AB5 architecture, including the structure of their catalytic domains their immunologic and adjuvant properties, characteristics and possible pathologic consequences of host cell receptor recognition, and the assembly and subunit interactions of these complex multimeric proteins.
Subject(s)
Bacterial Vaccines , Cholera Toxin/biosynthesis , Cholera Toxin/immunology , Pertussis Toxin , Pertussis Vaccine , Vaccines, Synthetic , Virulence Factors, Bordetella/biosynthesis , Virulence Factors, Bordetella/immunology , Adenosine Diphosphate Ribose/metabolism , Antigens, Bacterial/biosynthesis , Antigens, Bacterial/immunology , Bordetella pertussis/immunology , Child , Cholera Toxin/metabolism , Clinical Trials as Topic , Cloning, Molecular , Drug Design , Humans , Italy , Japan , Macromolecular Substances , Pertussis Vaccine/adverse effects , Recombinant Proteins/biosynthesis , Recombinant Proteins/immunology , United States , Virulence Factors, Bordetella/metabolismSubject(s)
Bacterial Toxins/immunology , Bacterial Vaccines , Cholera/immunology , Vaccines, Synthetic , Bacterial Infections/immunology , Bacterial Infections/prevention & control , Bacterial Toxins/chemistry , Cholera/prevention & control , Cholera Toxin/immunology , Drug Design , Humans , Models, Structural , Poly(ADP-ribose) Polymerases/chemistry , Poly(ADP-ribose) Polymerases/immunology , Protein Conformation , Recombinant ProteinsSubject(s)
Cholera Toxin/genetics , Cholera Toxin/immunology , Protein Engineering , Adjuvants, Immunologic/chemistry , Adjuvants, Immunologic/genetics , Cholera/prevention & control , Cholera Toxin/chemistry , Cholera Vaccines/genetics , Cholera Vaccines/immunology , Cholera Vaccines/isolation & purification , Humans , Molecular Structure , Mutagenesis, Site-Directed , Poly(ADP-ribose) Polymerases/chemistry , Poly(ADP-ribose) Polymerases/genetics , Poly(ADP-ribose) Polymerases/immunology , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccines, Synthetic/isolation & purification , Virulence Factors, Bordetella/chemistry , Virulence Factors, Bordetella/genetics , Virulence Factors, Bordetella/immunologyABSTRACT
To determine whether antibodies to the B oligomer of pertussis toxin (PT) were present in patients diagnosed with pertussis or vaccinees who had received diphtheria-tetanus-whole-cell pertussis vaccine, we analyzed serum samples from 5 patients and 10 vaccinees by both enzyme-linked immunosorbent assay (ELISA) and Western immunoblotting techniques. Antibodies to the B oligomer were detected by ELISA in all samples containing antibodies to holotoxin. Western immunoblotting procedures were less efficient than ELISA techniques for detecting antibodies to the B oligomer. Antibodies which inhibit the ability of the B oligomer to agglutinate erythrocytes were detected in purified human immunoglobulin preparations. In addition, serum samples containing antibodies to PT inhibited the binding of purified B oligomer and holotoxin to a 165-kDa glycoprotein which has been considered a potential PT receptor in Chinese hamster ovary (CHO) cells. These results suggest that antibodies to the B oligomer contribute to the human serologic response to PT, but their detection and characterization require appropriate methods.
Subject(s)
Pertussis Toxin , Virulence Factors, Bordetella/immunology , Animals , Antibodies, Bacterial/immunology , Antibody Formation , Antibody Specificity , Blotting, Western , CHO Cells/cytology , Cell Extracts/immunology , Cricetinae , Enzyme-Linked Immunosorbent Assay , Hemagglutination Inhibition Tests , Humans , Polymers , Protein Denaturation/immunologyABSTRACT
The catalytic A subunit of cholera toxin (CT-A) is capable of ADP-ribosylating the guanine nucleotide-binding protein, which regulates cell adenylyl cyclase, leading to the life-threatening diarrhea of cholera. Amino acids involved in the enzymatic activity of CT-A have previously been identified. By means of site-directed mutagenesis, an analog of the CT-A subunit gene was created with codon substitutions for both Arg-7 and Glu-112, each of which has been shown to produce subunits lacking ADP-ribosyltransferase activity. The mutated gene fragment was exchanged for the wild-type copy in the previously cloned ctxAB operon from El Tor biotype, Ogawa serotype Vibrio cholerae strain 3083, which produces CT-2. Further, the zonula occludens toxin gene, zot, was inactivated by an insertional mutation to create the new plasmid construct pCT-2*. Additionally, a DNA fragment encoding the B subunit of CT-1 (CT produced by classical biotype, Inaba serotype V. cholerae strain 569B) was exchanged for the homologous part in pCT-2*, resulting in the creation of pCT-1*. These plasmid constructs were introduced into the CT-negative V. cholerae mutant strain JBK70 (E1 Tor biotype, Inaba serotype); CT-A-B+ derivatives CVD101 and CVD103 of classical biotype Ogawa and Inaba serotype strains 395 and 569B, respectively; El Tor biotype Inaba and Ogawa serotype strains C6706 and C7258, respectively, recently isolated in Peru; and O139 (synonym Bengal) strain SG25-1 from the current epidemic in India. Recombinant toxins (CT-1* and CT-2*), partially purified from culture supernatants of transformed JBK70, were shown to be inactive on mouse Y1 adrenal tumor cells and in an in vitro ADP-ribosyltransferase assay. CT-1* and CT-2* reacted with polyclonal and monoclonal antibodies against both A and B subunits of CT. The toxin analogs reacted with antibodies against CT-A and CT-B on cellulose acetate strips and in a GM1 enzyme-linked immunosorbent assay; they reacted appropriately with B-subunit epitype-specific monoclonal antibodies in checkerboard immunoblots, and they formed precipitin bands with GM1-ganglioside in Ouchterlony tests. However, the reactions of the modified proteins with anti-A-subunit monoclonal antibodies were weaker than the reactions with wild-type holotoxins. V, cholerae strains carrying ctxA*, with either ctxB-1 or ctxB-2, and inactivated zot genes were created by homologous recombination. The recombinant strains and the purified toxin analogs were inactive in the infant rabbit animal model.(ABSTRACT TRUNCATED AT 400 WORDS)
Subject(s)
Cholera Toxin/biosynthesis , Cholera Vaccines/biosynthesis , Vaccines, Synthetic/biosynthesis , Vibrio cholerae/genetics , Animals , Base Sequence , Cholera Toxin/genetics , Cholera Toxin/toxicity , Genes, Bacterial , Molecular Sequence Data , Plasmids , RabbitsABSTRACT
The crystal structures recently determined for pertussis toxin, cholera toxin, and E. coli heat-labile toxins promise advances in rational vaccine design and improved understanding of G protein-mediated signal transduction.
Subject(s)
Bacterial Toxins/chemistry , Bacterial Vaccines , Cholera Toxin/chemistry , Enterotoxins/chemistry , GTP-Binding Proteins/physiology , Models, Structural , Pertussis Toxin , Signal Transduction , Virulence Factors, Bordetella/chemistry , Bacterial Toxins/metabolism , Cholera Toxin/metabolism , Drug Design , Enterotoxins/metabolism , Escherichia coli Proteins , Virulence Factors, Bordetella/metabolismSubject(s)
ADP Ribose Transferases/biosynthesis , Bacterial Toxins/biosynthesis , Cholera Toxin/biosynthesis , Enterotoxins/biosynthesis , Escherichia coli Proteins , Pertussis Vaccine/biosynthesis , Recombinant Proteins/biosynthesis , Vaccines, Synthetic/biosynthesis , ADP Ribose Transferases/chemistry , ADP Ribose Transferases/physiology , Bacterial Toxins/chemistry , Bordetella pertussis/genetics , Bordetella pertussis/metabolism , Cholera Toxin/chemistry , Enterotoxins/chemistry , Escherichia coli/genetics , Escherichia coli/metabolism , Genetic Engineering , Pertussis Toxin , Virulence Factors, Bordetella/biosynthesis , Virulence Factors, Bordetella/chemistryABSTRACT
The lectin domains of two subunits of pertussis toxin, S2 and S3, share amino acid sequence similarity with the lectin domains of the eukaryotic selectin family. During inflammation, selectins appear on endothelial cells and promote recruitment of leukocytes by reversibly binding carbohydrates. Synthetic peptides representing the carbohydrate recognition domains of S2 and S3 competitively inhibited adherence of neutrophils to endothelial cells in vitro. For some peptides, this antiinflammatory effect occurred without up-regulation of the function of the leukocyte integrin CD11b/CD18. Intravenous administration of peptides to animals with meningitis disrupted recruitment of leukocytes into the cerebrospinal fluid. These findings indicate that peptides derived from prokaryotic members of the selectin family have therapeutic antiinflammatory potential.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Meningitis/drug therapy , Pertussis Toxin , Virulence Factors, Bordetella/pharmacology , Amino Acid Sequence , Animals , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Antigens, CD/metabolism , CD18 Antigens , Cell Adhesion/drug effects , Cell Adhesion Molecules/chemistry , Cells, Cultured , Disease Models, Animal , E-Selectin , Humans , Integrins/metabolism , Leukocytes/drug effects , Leukocytes/metabolism , Macrophage-1 Antigen/metabolism , Molecular Sequence Data , P-Selectin , Peptide Fragments/chemistry , Peptide Fragments/pharmacology , Platelet Membrane Glycoproteins/chemistry , Rabbits , Sequence Homology, Amino Acid , Up-Regulation , Virulence Factors, Bordetella/chemistryABSTRACT
Pertussis toxin binds target cells through the carbohydrate recognition properties of two subunits, S2 and S3, which share amino acid sequence similarity with the lectin domains of the eukaryotic selectin family. Selectins appear on inflamed endothelial cells and promote rolling of leukocytes by reversibly binding carbohydrates. S2, S3, and synthetic peptides representing their carbohydrate recognition domains competitively inhibited adherence of neutrophils to selectin-coated surfaces and to endothelial cells in vitro. These proteins and peptides also rapidly upregulated the function of the leukocyte integrin CD11b/CD18. These findings implicate mimicry of eukaryotic selectins by prokaryotic adhesive ligands and link the mechanisms underlying leukocyte trafficking to microbial pathogenesis.
Subject(s)
Cell Adhesion Molecules/chemistry , Cell Adhesion Molecules/metabolism , Cell Adhesion , Pertussis Toxin , Platelet Membrane Glycoproteins/chemistry , Virulence Factors, Bordetella/chemistry , Amino Acid Sequence , Antigens, CD/metabolism , Binding, Competitive , CD18 Antigens , E-Selectin , Endothelium, Vascular/cytology , L-Selectin , Macrophage-1 Antigen/metabolism , Molecular Sequence Data , P-Selectin , Platelet Membrane Glycoproteins/metabolism , Sequence Alignment , Structure-Activity Relationship , Virulence Factors, Bordetella/metabolismABSTRACT
Pertussis toxin (PT) and filamentous hemagglutinin can each mediate the association of Bordetella pertussis with human macrophages. Adherence via filamentous hemagglutinin leads to integrin-mediated entry and survival of the bacteria within the human cell. We determined the contribution of PT to bacterial adherence to human macrophages. Plating macrophages on wells coated with recombinant PT subunit 2 (S2) or S3 decreased PT-dependent bacterial binding by greater than 60%; S1, S4, and S5 were ineffective. S3-dependent adherence was reduced 63% +/- 8% by sialic acid, while S2-dependent adherence was reduced 53% +/- 11% by galactose. Loss of the carbohydrate recognition properties of S2 by deletion of residues 40 to 54 or site-specific mutations at Asn-93, His-47, or Arg-50 eliminated the ability of the subunit protein to competitively inhibit bacterial binding. Peptides corresponding to residues 28 to 45 of S2 and S3 competitively inhibited adherence. Treatment of macrophages with antibodies to Le(a) or Le(x) but not CD14, CD15, CD18, or HLA interfered with PT-mediated binding. Exposure of the macrophages to the B oligomer, S2, or S3 increased binding to the CD11b/CD18 integrin. These results indicate that the carbohydrate recognition domains of both S2 and S3 participate in adherence of B. pertussis to human macrophages. The PT receptor(s), as yet unidentified, appears to carry the Le(a) or Le(x) determinants and is functionally capable of modulating integrin-mediated binding to the macrophage.
Subject(s)
Bacterial Adhesion , Bordetella pertussis/physiology , Carbohydrate Metabolism , Macrophages/microbiology , Pertussis Toxin , Virulence Factors, Bordetella/metabolism , Amino Acid Sequence , Antigens, CD/metabolism , Bordetella pertussis/pathogenicity , CD18 Antigens , Humans , Integrins/physiology , Molecular Sequence DataABSTRACT
The subunits that make up the pentameric B oligomer of pertussis toxin (S2, S3, S4, and S5) were individually synthesized as recombinant polypeptides in Escherichia coli, isolated as insoluble inclusion bodies, and assembled into a multimeric form in vitro by spontaneous association following treatment with a chaotropic agent, reduction, and reoxidation. The recombinant B multimer, purified by fetuin-Sepharose affinity chromatography, contained all four of the individual subunits and possessed the mitogenic and hemagglutinating activities characteristic of the native B oligomer. Immunization of mice with the recombinant B oligomer elicited antibodies that neutralized pertussis toxin in vitro and, moreover, provided protection in vivo against the leukocytosis-promoting activity of the toxin. These results demonstrate the potential for assembly of complex multimeric proteins from recombinant DNA-derived polypeptides and provide a novel means for production of an acellular pertussis vaccine component.
Subject(s)
Escherichia coli/metabolism , Pertussis Toxin , Virulence Factors, Bordetella/immunology , Animals , Antibodies, Bacterial/analysis , Immunization , Mice , Recombinant Proteins/biosynthesis , Recombinant Proteins/immunology , Virulence Factors, Bordetella/biosynthesisABSTRACT
Bordetella pertussis is bound to glycoconjugates on human cilia and macrophages by multiple adhesins, including pertussis toxin. The cellular recognition properties of the B oligomer of pertussis toxin were characterized and the location and structural requirements of the recognition domains were identified by site-directed mutagenesis of recombinant pertussis toxin subunits. Differential recognition of cilia and macrophages, respectively, was localized to subunits S2 and S3 of the B oligomer. Despite greater than 80% sequence homology between these subunits, ciliary lactosylceramide exclusively recognized S2 and leukocytic gangliosides bound only S3. Substitution at residue 44, 45, 50, or 51 in S2 resulted in a shift of carbohydrate recognition from lactosylceramide to gangliosides. Mutational exchange of amino acid residues 37-52 between S2 and S3 interchanged their carbohydrate and target cell specificity. Comparison of these carbohydrate recognition sequences to those of plant and animal lectins revealed that regions essential for function of the prokaryotic lectins were strongly related to a subset of eukaryotic carbohydrate recognition domains of the C type.
Subject(s)
Bacterial Adhesion , Carbohydrate Metabolism , Pertussis Toxin , Virulence Factors, Bordetella/chemistry , Amino Acid Sequence , DNA Mutational Analysis , Epithelium/microbiology , Glycolipids/metabolism , In Vitro Techniques , Lectins/chemistry , Macrophages/microbiology , Molecular Sequence Data , Protein Binding , Restriction Mapping , Structure-Activity Relationship , Virulence Factors, Bordetella/geneticsABSTRACT
Research that may lead to the development of recombinant DNA-based vaccines has been conducted on a broad front. This has resulted in an increased understanding of immunological responsiveness to vaccines, the rational engineering of immunogens, and new means of delivering vaccines.
Subject(s)
Vaccines, Synthetic , AIDS Vaccines , Amino Acid Sequence , Animals , Humans , Molecular Sequence Data , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunologyABSTRACT
Cholera and pertussis toxins each contain a subunit with ADP-ribosyltransferase activity, sharing a region of nearly identical amino acid sequence near the NH2 terminus. Previous investigations have shown that substitution of a lysine residue for Arg-9 in the catalytic A subunit of pertussis toxin substantially eliminates its enzyme activity. We now report that substitution of lysine for the position-equivalent Arg-7 of cholera toxin subunit A leads to a similar loss of catalytic activity. This result suggests a correlation of function with structure between the sequence-related cholera and pertussis toxin A subunits and may contribute to the design of a vaccine containing an enzymatically inert analog of cholera toxin.
Subject(s)
Cholera Toxin/genetics , Arginine/chemistry , Cholera Toxin/toxicity , Cloning, Molecular , DNA Mutational Analysis , Lysine/chemistry , NAD/metabolism , Poly(ADP-ribose) Polymerases/genetics , Poly(ADP-ribose) Polymerases/metabolism , Recombinant Proteins/toxicity , Structure-Activity RelationshipABSTRACT
An enzymatically deficient recombinant S1 subunit, in which Arg-9 was replaced by Lys, was combined with native B oligomer to form a mutant holotoxin molecule. This molecule exhibited decreased leukocytosis-promoting and histamine-sensitizing activities compared with those of the native toxin, supporting the view that the B oligomer is not responsible for these activities. The protective activity of this genetically attenuated pertussis toxin was compared with that of B oligomer alone. The mutant pertussis toxin and B oligomer were similarly capable of protecting mice against a respiratory infection with Bordetella pertussis, suggesting that the B oligomer makes a significant contribution to the protection afforded by the genetically attenuated holotoxin.
Subject(s)
Pertussis Toxin , Pertussis Vaccine/immunology , Vaccines, Synthetic/immunology , Virulence Factors, Bordetella/immunology , Animals , Antibodies, Bacterial/analysis , Cricetinae , Female , Immunization , Mice , Mice, Inbred BALB C , Vaccines, Attenuated/immunologyABSTRACT
The demand for a safer pertussis vaccine has led to the development of acellular vaccine products. We have sought to manufacture a component vaccine based upon the genetic inactivation of pertussis toxin derived by recombinant DNA technology and protein engineering. Rational site-directed mutagenesis of the S1 subunit of pertussis toxin has resulted in an enzymatically-deactivated polypeptide which retains its immunogenic potential. Mutagenic analysis of the other subunits of this toxin has permitted a delineation of the structural determinants involved in its recognition of cellular receptors. The in vitro assembly of holotoxin species possessing selectively engineered subunits may facilitate the production of a molecularly-defined genetic toxoid for pertussis prophylaxis.
Subject(s)
Toxoids/genetics , Genetic Engineering , Humans , Mutagenesis, Site-Directed , Pertussis Vaccine/isolation & purification , Vaccines, Synthetic/isolation & purification , Whooping Cough/prevention & controlSubject(s)
Pertussis Vaccine/immunology , Vaccines, Synthetic/immunology , Antigens, Bacterial/genetics , Antigens, Bacterial/immunology , Bordetella pertussis/genetics , Bordetella pertussis/immunology , Humans , Mutagenesis, Site-Directed/genetics , Pertussis Vaccine/genetics , Vaccines, Synthetic/genetics , Virulence Factors, Bordetella/genetics , Virulence Factors, Bordetella/immunology , Whooping Cough/prevention & controlABSTRACT
The S1 subunit of pertussis toxin catalyses the hydrolysis of NAD+ (NAD+ glycohydrolysis) and the NAD(+)-dependent ADP-ribosylation of guanine-nucleotide-binding proteins. Recently, the S1 subunit of pertussis toxin was shown to be photolabelled by using radiolabelled NAD+ and u.v.; the primary labelled residue was Glu-129, thereby implicating this residue in the binding of NAD+. Studies from various laboratories have shown that the N-terminal portion of the S1 subunit, which shows sequence similarity to cholera toxin and Escherichia coli heat-labile toxin, is important to the maintenance of both glycohydrolase and transferase activity. In the present study the photolabelling technique was applied to the analysis of a series of recombinant-derived S1 molecules that possessed deletions or substitutions near the N-terminus of the S1 molecule. The results revealed a positive correlation between the extent of photolabelling with NAD+ and the magnitude of specific NAD+ glycohydrolase activity exhibited by the mutants. Enzyme kinetic analyses of the N-terminal mutants also identified a mutant with substantially reduced activity, a depressed photolabelling efficiency and a markedly increased Km for NAD+. The results support a direct role for the N-terminal region of the S1 subunit in the binding of NAD+, thereby providing a rationale for the effect of mutations in this region on enzymic activity.